JP2023526259A - がんまたは腫瘍の治療の方法 - Google Patents

がんまたは腫瘍の治療の方法 Download PDF

Info

Publication number
JP2023526259A
JP2023526259A JP2022568820A JP2022568820A JP2023526259A JP 2023526259 A JP2023526259 A JP 2023526259A JP 2022568820 A JP2022568820 A JP 2022568820A JP 2022568820 A JP2022568820 A JP 2022568820A JP 2023526259 A JP2023526259 A JP 2023526259A
Authority
JP
Japan
Prior art keywords
cancer
cells
seq
tumor
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526259A5 (enExample
Inventor
エドワード ダッドリー，マーク
Original Assignee
アダプティミューン・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダプティミューン・リミテッド filed Critical アダプティミューン・リミテッド
Publication of JP2023526259A publication Critical patent/JP2023526259A/ja
Publication of JP2023526259A5 publication Critical patent/JP2023526259A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/51—Stomach
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022568820A 2020-05-13 2021-05-13 がんまたは腫瘍の治療の方法 Pending JP2023526259A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063024104P 2020-05-13 2020-05-13
US63/024,104 2020-05-13
PCT/GB2021/051158 WO2021229235A1 (en) 2020-05-13 2021-05-13 Method of treatment of cancer or tumour

Publications (2)

Publication Number Publication Date
JP2023526259A true JP2023526259A (ja) 2023-06-21
JP2023526259A5 JP2023526259A5 (enExample) 2025-03-27

Family

ID=76098971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568820A Pending JP2023526259A (ja) 2020-05-13 2021-05-13 がんまたは腫瘍の治療の方法

Country Status (7)

Country Link
US (1) US20230190802A1 (enExample)
EP (1) EP4149631A1 (enExample)
JP (1) JP2023526259A (enExample)
CN (1) CN116194472A (enExample)
AU (1) AU2021270378A1 (enExample)
CA (1) CA3178588A1 (enExample)
WO (1) WO2021229235A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
GB202205572D0 (en) * 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
CN116449016A (zh) * 2022-08-26 2023-07-18 成都益安博生物技术有限公司 一种食管癌的外周血tcr标志物序列及其检测试剂盒和应用
GB202213050D0 (en) * 2022-09-07 2022-10-19 Adaptimmune Ltd Method of treatment of gastroesophageal cancer
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
WO2024163440A1 (en) * 2023-01-31 2024-08-08 Agilent Technologies, Inc. Immunohistochemistry (ihc) mage-a4 scoring protocols and methods for aiding cancer treatments
CN120594199B (zh) * 2025-08-06 2025-11-07 浙江省肿瘤医院 Mhc-ii表达在胃癌免疫治疗疗效预测中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528748A (ja) * 2016-09-23 2019-10-17 アダプティミューン・リミテッド 免疫抑制抵抗性が増したｔ細胞
WO2020049496A1 (en) * 2018-09-05 2020-03-12 Glaxosmithkline Intellectual Property Development Limited T cell modification
JP2020509767A (ja) * 2017-03-15 2020-04-02 フレッド ハッチンソン キャンサー リサーチ センター 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
GB2613715B (en) * 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
AU2021208433A1 (en) * 2020-01-14 2022-07-14 Uswm Ct, Llc Method of treatment of cancer or tumour

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528748A (ja) * 2016-09-23 2019-10-17 アダプティミューン・リミテッド 免疫抑制抵抗性が増したｔ細胞
JP2020509767A (ja) * 2017-03-15 2020-04-02 フレッド ハッチンソン キャンサー リサーチ センター 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用
WO2020049496A1 (en) * 2018-09-05 2020-03-12 Glaxosmithkline Intellectual Property Development Limited T cell modification

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Enhanced activity of second-generation MAGE-A4 SPEAR T-cells through co-expression of a CD8α homodi", CANCER RES., vol. Vol.79, No.13_Supplement, JPN6025031524, 2019, pages 2313, ISSN: 0005656762 *
"Initial safety assessment of MAGE-A4 SPEAR T-cells", IMMUNOTHERAPY OF CANCER, vol. Vol.29, Suppl.8, JPN6025031523, 2018, pages 412 - 1156, ISSN: 0005656763 *
J. CLIN. MED., vol. Vol.5, No.84, doi:10.3390/jcm5100084, JPN6025031522, 2016, pages 1 - 14, ISSN: 0005656761 *
ONCOIMMUNOLOGY, vol. Vol.9, No.1, e1682381, JPN6025031525, 24 November 2019 (2019-11-24), pages 1682381 - 1, ISSN: 0005656760 *

Also Published As

Publication number Publication date
CA3178588A1 (en) 2021-11-18
US20230190802A1 (en) 2023-06-22
AU2021270378A1 (en) 2022-12-15
CN116194472A (zh) 2023-05-30
EP4149631A1 (en) 2023-03-22
WO2021229235A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
Yu et al. Advances on immunotherapy for osteosarcoma
US20230190802A1 (en) Method of treatment of cancer or tumour
Barr et al. Recent advances and remaining challenges in lung cancer therapy
US20230190803A1 (en) Method of treatment of cancer or tumour
Hannouneh et al. Novel immunotherapeutic options for BCG‐unresponsive high‐risk non‐muscle‐invasive bladder cancer
US20220370559A1 (en) Method of treatment of cancer or tumour
JP2022500022A (ja) Ｔ細胞改変
Triplett et al. STAT3 signaling is required for optimal regression of large established tumors in mice treated with anti-OX40 and TGFβ receptor blockade
Ascierto et al. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018”(28–29 November, 2018, Naples, Italy)
US20220390433A1 (en) Methods of treatment with cd8 t cell-mediated immune therapy
US20230398185A1 (en) Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer
US20230390334A1 (en) Method of treatment of cancer or tumour
CN117425492A (zh) 双特异性t细胞接合剂的给药
US20260069692A1 (en) Modified t-cells for use in the treatment of gastroesophageal cancer
US20260116976A1 (en) Genetically defined immune-checkpoint inhibitor resistance in aggressive precursors of hpv--head and neck squamous cancer
JP2025530188A (ja) 膀胱がんの治療において使用するための改変ｔ細胞
Aspeslagh et al. Development of Immunotherapeutic Strategies for Early Phase Clinical Trials
JP2025530187A (ja) 頭頚部がんの治療において使用するための改変ｔ細胞
Slavyanskaya et al. Precision oncology: myth or reality?
Taitt et al. Let us know how access to this document benefits yo u

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310